×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ADVM – adverum biotechnologies, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ADVM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/20
04:05 pm
advm
Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11/20
12:04 am
advm
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
High
Report
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/19
08:20 am
advm
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
High
Report
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
11/18
07:12 am
advm
Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements [Yahoo! Finance]
High
Report
Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements [Yahoo! Finance]
11/18
07:00 am
advm
Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements
High
Report
Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements
11/15
04:05 pm
advm
Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements
Low
Report
Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements
11/6
11:09 pm
advm
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/5
11:19 am
advm
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its price target lowered by analysts at Royal Bank of Canada from $12.00 to $10.00. They now have a "sector perform" rating on the stock.
Low
Report
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its price target lowered by analysts at Royal Bank of Canada from $12.00 to $10.00. They now have a "sector perform" rating on the stock.
Date
Time
Symbol
Headline
Impact
11/18
04:07 pm
advm
Form 8-K Adverum Biotechnologies, For: Nov 18
Medium
Report
Form 8-K Adverum Biotechnologies, For: Nov 18
11/14
06:57 pm
advm
Form SC 13G/A Adverum Biotechnologies, Filed by: Vivo Opportunity Fund Holdings, L.P.
Medium
Report
Form SC 13G/A Adverum Biotechnologies, Filed by: Vivo Opportunity Fund Holdings, L.P.
11/14
06:41 pm
advm
Form SC 13G/A Adverum Biotechnologies, Filed by: Logos Global Management LP
Medium
Report
Form SC 13G/A Adverum Biotechnologies, Filed by: Logos Global Management LP
11/14
04:06 pm
advm
Form SC 13G/A Adverum Biotechnologies, Filed by: COMMODORE CAPITAL LP
Medium
Report
Form SC 13G/A Adverum Biotechnologies, Filed by: COMMODORE CAPITAL LP
11/12
09:51 am
advm
Form SC 13G/A Adverum Biotechnologies, Filed by: FMR LLC
Low
Report
Form SC 13G/A Adverum Biotechnologies, Filed by: FMR LLC
11/8
02:20 pm
advm
Form SC 13G Adverum Biotechnologies, Filed by: BlackRock, Inc.
Low
Report
Form SC 13G Adverum Biotechnologies, Filed by: BlackRock, Inc.
11/6
05:50 pm
advm
Form SC 13G/A Adverum Biotechnologies, Filed by: MORGAN STANLEY
Low
Report
Form SC 13G/A Adverum Biotechnologies, Filed by: MORGAN STANLEY
11/4
04:45 pm
advm
Form 10-Q Adverum Biotechnologies, For: Sep 30
Low
Report
Form 10-Q Adverum Biotechnologies, For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/12
Adverum Biotechnologies Inc (NASDAQ: ADVM) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.
30.8%
5/16 Adverum Biotechnologies Provides Update on OPTIC Phase 1 Trial for ADVM-022 in Wet AMD 26.0%
2/10 Form 424B5 Adverum Biotechnologies, 23.8%
7/8 Adverum Biotechnologies to Present Data at Upcoming Conferences 22.5%
2/9 Adverum Biotechnologies Inc (NASDAQ: ADVM) was upgraded by analysts at Cantor Fitzgerald from a "neutral" rating to an "overweight" rating. 21.0%
3/18 Form 4 Adverum Biotechnologies, For: Mar 17 Filed by: PATTERSON LEONE D 17.0%
10/11 Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting 15.1%
3/19 Adverum Biotechnologies Inc (NASDAQ: ADVM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 12.2%
3/25 Form 4 Adverum Biotechnologies, For: Mar 20 Filed by: PATTERSON LEONE D 9.2%
10/31 Adverum Biotechnologies to Host a Conference Call and Webcast to Report Third Quarter 2019 Financial Results and Provide Corporate Updates 8.8%
5/16 Adverum Biotechnologies Provides Update on OPTIC Phase 1 Trial for ADVM-022 in Wet AMD 26.0%
2/10 Form 424B5 Adverum Biotechnologies, 23.8%
7/8 Adverum Biotechnologies to Present Data at Upcoming Conferences 22.5%
2/9 Adverum Biotechnologies Inc (NASDAQ: ADVM) was upgraded by analysts at Cantor Fitzgerald from a "neutral" rating to an "overweight" rating. 21.0%
3/18 Form 4 Adverum Biotechnologies, For: Mar 17 Filed by: PATTERSON LEONE D 17.0%
10/11 Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting 15.1%
3/19 Adverum Biotechnologies Inc (NASDAQ: ADVM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 12.2%
3/25 Form 4 Adverum Biotechnologies, For: Mar 20 Filed by: PATTERSON LEONE D 9.2%
10/31 Adverum Biotechnologies to Host a Conference Call and Webcast to Report Third Quarter 2019 Financial Results and Provide Corporate Updates 8.8%
TOP News Decliners
3/11
Adverum Biotechnologies Announces Data Presentations at ARVO 2020
-13.8%
3/16 Adverum Biotechnologies Inc (NASDAQ: ADVM) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating on the stock. -13.2%
8/1 Adverum Biotechnologies Announces Board and Senior Management Changes -12.6%
2/10 Adverum Biotechnologies Inc (NASDAQ: ADVM) was upgraded by analysts at Chardan Capital from a "neutral" rating to a "buy" rating. They now have a $20.00 price target on the stock, up previously from $10.00. -11.8%
4/20 Adverum Biotechnologies Appoints Ophthalmology Industry Veteran Scott Whitcup, M.D. to Board of Directors -11.6%
3/5 Adverum Biotechnologies to Host a Conference Call and Webcast to Report Fourth Quarter 2019 Financial Results and Provide Corporate Update -10.7%
9/13 Adverum Biotechnologies Inc (NASDAQ: ADVM) had its price target lowered by analysts at Chardan Capital from $10.00 to $6.00. They now have a "neutral" rating on the stock. -10.4%
4/29 Adverum Biotechnologies Inc (NASDAQ: ADVM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.5%
3/11 Adverum Biotechnologies Inc (NASDAQ: ADVM) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -9.4%
3/2 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM -9.1%
3/16 Adverum Biotechnologies Inc (NASDAQ: ADVM) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating on the stock. -13.2%
8/1 Adverum Biotechnologies Announces Board and Senior Management Changes -12.6%
2/10 Adverum Biotechnologies Inc (NASDAQ: ADVM) was upgraded by analysts at Chardan Capital from a "neutral" rating to a "buy" rating. They now have a $20.00 price target on the stock, up previously from $10.00. -11.8%
4/20 Adverum Biotechnologies Appoints Ophthalmology Industry Veteran Scott Whitcup, M.D. to Board of Directors -11.6%
3/5 Adverum Biotechnologies to Host a Conference Call and Webcast to Report Fourth Quarter 2019 Financial Results and Provide Corporate Update -10.7%
9/13 Adverum Biotechnologies Inc (NASDAQ: ADVM) had its price target lowered by analysts at Chardan Capital from $10.00 to $6.00. They now have a "neutral" rating on the stock. -10.4%
4/29 Adverum Biotechnologies Inc (NASDAQ: ADVM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.5%
3/11 Adverum Biotechnologies Inc (NASDAQ: ADVM) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -9.4%
3/2 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM -9.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: